“Regulatory is sexy and quality is not” says David Amor, Vice President of Quality and Regulatory Affairs at Pear Therapeutics. Digital therapeutics will need to meet quality standards like those required by conventional drugs. The company is also working on a new drug for treating multiple sclerosis (MS). The USP is looking to introduce standards that will enable doctors to confidently use the new treatments, said Ronald Piervincenzi, CEO of USP. Joris Van Dam, head of digital therapeutics at Novartis, said early software testing could be likened to preclinical studies for drugs.
Digital therapeutics will need to meet quality standards like those required by conventional drugs. The company is also working on a new drug for treating multiple sclerosis (MS). The USP is looking to introduce standards that will enable doctors to confidently use the new treatments, said Ronald Piervincenzi, CEO of USP. Joris Van Dam, head of digital therapeutics at Novartis, said early software testing could be likened to preclinical studies for drugs.